{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T17:51:09Z","timestamp":1792086669102,"version":"4.4.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:00:00Z","timestamp":1792022400000},"content-version":"vor","delay-in-days":92,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Immunol"],"DOI":"10.1186\/s12865-026-00879-9","type":"journal-article","created":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T10:26:26Z","timestamp":1784111186000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Evaluation of the efficacy and safety of Iguratimod combined with traditional anti-rheumatic drugs in treating rheumatoid arthritis: a retrospective study"],"prefix":"10.1186","volume":"27","author":[{"given":"Xueqin","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zongwen","family":"Shuai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiangli","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xixi","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linwei","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,15]]},"reference":[{"issue":"11","key":"879_CR1","doi-asserted-by":"publisher","first-page":"2857","DOI":"10.3390\/cells10112857","volume":"10","author":"A-F Radu","year":"2021","unstructured":"Radu A-F, Bungau SG. Management of Rheumatoid Arthritis: An Overview. Cells. 2021;10(11):2857.","journal-title":"Cells"},{"key":"879_CR2","doi-asserted-by":"publisher","first-page":"686155","DOI":"10.3389\/fimmu.2021.686155","volume":"12","author":"J Huang","year":"2021","unstructured":"Huang J, Fu X, Chen X, Li Z, Huang Y, Liang C. Promising Therapeutic Targets for Treatment of Rheumatoid Arthritis. Front Immunol. 2021;12:686155.","journal-title":"Front Immunol"},{"issue":"9","key":"879_CR3","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1080\/1744666X.2022.2106970","volume":"18","author":"AI Venetsanopoulou","year":"2022","unstructured":"Venetsanopoulou AI, Alamanos Y, Voulgari PV, Drosos AA. Epidemiology of rheumatoid arthritis: genetic and environmental influences. Expert Rev Clin Immunol. 2022;18(9):923\u201331.","journal-title":"Expert Rev Clin Immunol"},{"key":"879_CR4","doi-asserted-by":"publisher","first-page":"1051082","DOI":"10.3389\/fimmu.2022.1051082","volume":"13","author":"D Wu","year":"2022","unstructured":"Wu D, Luo Y, Li T, Zhao X, Lv T, Fang G, Ou P, Li H, Luo X, Huang A, et al. Systemic complications of rheumatoid arthritis: Focus on pathogenesis and treatment. Front Immunol. 2022;13:1051082.","journal-title":"Front Immunol"},{"issue":"11","key":"879_CR5","doi-asserted-by":"publisher","first-page":"3017","DOI":"10.3390\/cells10113017","volume":"10","author":"A-L Mueller","year":"2021","unstructured":"Mueller A-L, Payandeh Z, Mohammadkhani N, Mubarak SMH, Zakeri A, Alagheband Bahrami A, Brockmueller A, Shakibaei M. Recent Advances in Understanding the Pathogenesis of Rheumatoid Arthritis: New Treatment Strategies. Cells. 2021;10(11):3017.","journal-title":"Cells"},{"issue":"12","key":"879_CR6","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s11926-023-01117-6","volume":"25","author":"C Conran","year":"2023","unstructured":"Conran C, Kolfenbach J, Kuhn K, Striebich C, Moreland L. A Review of Difficult-to-Treat Rheumatoid Arthritis: Definition, Clinical Presentation, and Management. Curr Rheumatol Rep. 2023;25(12):285\u201394.","journal-title":"Curr Rheumatol Rep"},{"key":"879_CR7","doi-asserted-by":"publisher","first-page":"113074","DOI":"10.1016\/j.biopha.2022.113074","volume":"150","author":"Z Zhao","year":"2022","unstructured":"Zhao Z, Hua Z, Luo X, Li Y, Yu L, Li M, Lu C, Zhao T, Liu Y. Application and pharmacological mechanism of methotrexate in rheumatoid arthritis. Biomed Pharmacother. 2022;150:113074.","journal-title":"Biomed Pharmacother"},{"issue":"5","key":"879_CR8","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1093\/mr\/roac126","volume":"33","author":"Y Tanaka","year":"2023","unstructured":"Tanaka Y, Kawanishi M, Nakanishi M, Yamasaki H, Takeuchi T. Efficacy and safety of anti-TNF multivalent NANOBODY\u00ae compound \u2018ozoralizumab\u2019 without methotrexate co-administration in patients with active rheumatoid arthritis: A 52-week result of phase III, randomised, open-label trial (NATSUZORA trial). Mod Rheumatol. 2023;33(5):875\u201382.","journal-title":"Mod Rheumatol"},{"key":"879_CR9","doi-asserted-by":"publisher","first-page":"1150661","DOI":"10.3389\/fimmu.2023.1150661","volume":"14","author":"Z Long","year":"2023","unstructured":"Long Z, Zeng L, He Q, Yang K, Xiang W, Ren X, Deng Y, Chen H. Research progress on the clinical application and mechanism of iguratimod in the treatment of autoimmune diseases and rheumatic diseases. Front Immunol. 2023;14:1150661.","journal-title":"Front Immunol"},{"issue":"6","key":"879_CR10","doi-asserted-by":"publisher","first-page":"e932","DOI":"10.1002\/iid3.932","volume":"11","author":"F Yuan","year":"2023","unstructured":"Yuan F, He J, Luo J, Zhang X, Lin J, Chen Y, Huang H, Yang Q. Iguratimod efficacy in palindromic rheumatism treatment. Immun Inflamm Dis. 2023;11(6):e932.","journal-title":"Immun Inflamm Dis"},{"issue":"3","key":"879_CR11","doi-asserted-by":"publisher","first-page":"e003317","DOI":"10.1136\/rmdopen-2023-003317","volume":"9","author":"A Kivitz","year":"2023","unstructured":"Kivitz A, Wang L, Alevizos I, Gunsior M, Falloon J, Illei G, St Clair EW. The MIDORA trial: a phase II, randomised, double-blind, placebo-controlled, mechanistic insight and dosage optimisation study of the efficacy and safety of dazodalibep in patients with rheumatoid arthritis. RMD Open. 2023;9(3):e003317.","journal-title":"RMD Open"},{"issue":"10","key":"879_CR12","doi-asserted-by":"publisher","first-page":"e2335950","DOI":"10.1001\/jamanetworkopen.2023.35950","volume":"6","author":"LS Guski","year":"2023","unstructured":"Guski LS, J\u00fcrgens G, Pedder H, Levinsen NKG, Andersen SE, Welton NJ, Graudal N. Monotreatment With Conventional Antirheumatic Drugs or Glucocorticoids in Rheumatoid Arthritis: A Network Meta-Analysis. JAMA Netw Open. 2023;6(10):e2335950.","journal-title":"JAMA Netw Open"},{"issue":"1","key":"879_CR13","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1080\/14656566.2023.2297798","volume":"25","author":"AI Venetsanopoulou","year":"2024","unstructured":"Venetsanopoulou AI, Voulgari PV, Drosos AA. Advances in non-biological drugs for the treatment of rheumatoid arthritis. Expert Opin Pharmacother. 2024;25(1):45\u201353.","journal-title":"Expert Opin Pharmacother"},{"issue":"3","key":"879_CR14","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1097\/CM9.0000000000002577","volume":"136","author":"H Huang","year":"2023","unstructured":"Huang H, Chen R, Shao C, Xu Z, Wolters PJ. Diffuse lung involvement in rheumatoid arthritis: a respiratory physician\u2019s perspective. Chin Med J (Engl). 2023;136(3):280\u20136.","journal-title":"Chin Med J (Engl)"},{"issue":"4","key":"879_CR15","doi-asserted-by":"publisher","first-page":"102786","DOI":"10.1016\/j.autrev.2021.102786","volume":"20","author":"B Hadwen","year":"2021","unstructured":"Hadwen B, Stranges S, Barra L. Risk factors for hypertension in rheumatoid arthritis patients-A systematic review. Autoimmun Rev. 2021;20(4):102786.","journal-title":"Autoimmun Rev"},{"issue":"10","key":"879_CR16","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.3899\/jrheum.210217","volume":"48","author":"G Jansen","year":"2021","unstructured":"Jansen G, de Rotte MCFJ, de Jonge R. Smoking and Methotrexate Inefficacy in Rheumatoid Arthritis: What About Underlying Molecular Mechanisms? J Rheumatol. 2021;48(10):1495\u20137.","journal-title":"J Rheumatol"},{"key":"879_CR17","doi-asserted-by":"publisher","first-page":"102227","DOI":"10.1016\/j.coph.2022.102227","volume":"64","author":"CM Garc\u00eda-Gonz\u00e1lez","year":"2022","unstructured":"Garc\u00eda-Gonz\u00e1lez CM, Baker J. Treatment of early rheumatoid arthritis: Methotrexate and beyond. Curr Opin Pharmacol. 2022;64:102227.","journal-title":"Curr Opin Pharmacol"},{"issue":"5","key":"879_CR18","doi-asserted-by":"publisher","first-page":"105602","DOI":"10.1016\/j.jbspin.2023.105602","volume":"90","author":"J-M Berthelot","year":"2023","unstructured":"Berthelot J-M, Liot\u00e9 F, Sibilia J. Methotrexate also improves rheumatoid arthritis through correction of microbiota dysbiosis. Joint Bone Spine. 2023;90(5):105602.","journal-title":"Joint Bone Spine"},{"issue":"1","key":"879_CR19","doi-asserted-by":"publisher","first-page":"5684293","DOI":"10.1155\/2022\/5684293","volume":"2022","author":"L Deng","year":"2022","unstructured":"Deng L, Yao F, Tian F, Luo X, Yu S, Wen Z. Influence of Iguratimod on Bone Metabolism in Patients with Rheumatoid Arthritis: A Meta-analysis. Int J Clin Pract. 2022;2022(1):5684293.","journal-title":"Int J Clin Pract"},{"key":"879_CR20","doi-asserted-by":"publisher","first-page":"110913","DOI":"10.1016\/j.intimp.2023.110913","volume":"124Pt B","author":"J Chen","year":"2023","unstructured":"Chen J, Che Q, Kou Y, Rong X, Zhang X, Li M, Shu Q. A novel drug combination of Tofacitinib and Iguratimod alleviates rheumatoid arthritis and secondary osteoporosis. Int Immunopharmacol. 2023;124Pt B:110913.","journal-title":"Int Immunopharmacol"},{"issue":"10","key":"879_CR21","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.12998\/wjcc.v9.i10.2181","volume":"9","author":"S Liu","year":"2021","unstructured":"Liu S, Song L-P, Li R-B, Feng L-H, Zhu H. Iguratimod promotes transformation of mononuclear macrophages in elderly patients with rheumatoid arthritis by nuclear factor-\u03baB pathway. World J Clin Cases. 2021;9(10):2181\u201391.","journal-title":"World J Clin Cases"},{"issue":"1","key":"879_CR22","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s41927-025-00475-1","volume":"9","author":"M Kaboli","year":"2025","unstructured":"Kaboli M, Nakhjavani M, ,Rabizadeh S, et al. The impact of anti-TNF-\u03b1 therapy on leptin and inflammatory markers in rheumatoid arthritis patients: a case-control study. BMC Rheumatol. 2025;9(1):22\u201322.","journal-title":"BMC Rheumatol"},{"key":"879_CR23","doi-asserted-by":"publisher","first-page":"780154","DOI":"10.3389\/fphar.2021.780154","volume":"12","author":"L Zeng","year":"2022","unstructured":"Zeng L, Yu G, Yang K, Hao W, Chen H. The Effect and Safety of Iguratimod Combined With Methotrexate on Rheumatoid Arthritis: A Systematic Review and Meta-Analysis Based on a Randomized Controlled Trial. Front Pharmacol. 2022;12:780154.","journal-title":"Front Pharmacol"},{"issue":"10","key":"879_CR24","doi-asserted-by":"publisher","first-page":"4007","DOI":"10.1007\/s10067-021-05746-z","volume":"40","author":"S Shrestha","year":"2021","unstructured":"Shrestha S, Zhao J, Yang C, Zhang J. Iguratimod combination therapy compared with methotrexate monotherapy for the treatment of rheumatoid arthritis: a systematic review and meta-analysis. Clin Rheumatol. 2021;40(10):4007\u201317.","journal-title":"Clin Rheumatol"},{"issue":"11","key":"879_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10792-020-01490-6","volume":"40","author":"J Wei","year":"2020","unstructured":"Wei J, Lingshu Z, ,Yi Z, et al. The efficacy and mechanism for action of iguratimod in primary Sj\u00f6gren\u2019s syndrome patients. Int Ophthalmol. 2020;40(11):1\u20137.","journal-title":"Int Ophthalmol"}],"container-title":["BMC Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12865-026-00879-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12865-026-00879-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12865-026-00879-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T17:34:08Z","timestamp":1792085648000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12865-026-00879-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,15]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["879"],"URL":"https:\/\/doi.org\/10.1186\/s12865-026-00879-9","relation":{},"ISSN":["1471-2172"],"issn-type":[{"value":"1471-2172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,15]]},"assertion":[{"value":"28 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethical approval was obtained from the Ethics Committee of Affiliated Chaohu Hospital of Anhui Medical University (Approval no. KYXM-202201-012).The requirement for written informed consent was waived by the Ethics Committee because this retrospective study used de-identified clinical data and posed minimal risk to participants.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"96"}}